NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Allogenetics

Allogenetics

Private
GermanyHealthcare & Life Scienceshttps://allogenetics.de/

Last Round

Seed

Sep 4, 2024

Total Funding Raised

$3.77M

Company Overview

Allogenetics is a biotechnology company developing a therapeutic approach that treats a donor organ to prevent rejection by the recipient's immune system.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

ex vivo gene therapyorgan transplant rejectiontransplant engineeringimmunomodulationHLA knockdownMHC knockdownorgan perfusionbiotech therapeuticstransplant medicinexenotransplantation alternativeimmune invisibilitygraft survivaltransplant immunologyregenerative medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Allogenetics Comps

Public and private peers based on sector, stage, and business model.

Allogenetics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Allogenetics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 4, 2024

Key People

Founding team and executive leadership

Frank Schnieders

Chief Development Officer Managing Director, Chief Executive Officer

Executive Team

Oliver Ernst

Managing Director I CEO - Biotech

Executive Team

Gaurav Dular

Chief Financial Officer

Executive Team

Allogenetics Investors

Notable investors and investment history

Allogenetics investors
InvestorRounds
AscenionSeed
NBank CapitalSeed
CARMA FUNDSeed

Allogenetics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Allogenetics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Allogenetics's valuation, stock price, and market status.

Firmographic Details

HeadquartersGermany
Employee Range16
Year Founded2022
Last FundingSep 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.